At its Annual Meeting of Shareholders today in Chicago, The Female Health Company (NASDAQ-CM: FHCO) announced that it expects to report record unit shipments and operating earnings for the fiscal year ending September 30, 2012.
"We reported a strong start to the fiscal year with outstanding first quarter sales and earnings results, and based on current and anticipated product orders, we expect to ship a record number of FC2 Female Condoms® and to achieve record operating earnings in Fiscal 2012," said O. B. Parrish, Chairman and Chief Executive Officer of The Female Health Company. "The previous record was set in Fiscal 2009, when the Company shipped 40.1 million units and reported operating income of $6.2 million, excluding restructuring charges."
In its most recent fiscal year, which ended September 30, 2011, the Company shipped 32.9 million FC2 Female Condoms and generated operating income of $3.3 million.
As noted in previous Female Health Company news releases, timing issues regarding the receipt and shipment of large orders can significantly impact the Company's operating results, positively or negatively, illustrating the difficulty of providing specific sales and operating earnings guidance. In the future, the Company intends to periodically provide general comments regarding its outlook, based upon information available at the time.
About The Female Health Company
The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC2 Female Condom® (FC2), which is available in the U.S. and approximately 130 other countries. The Company owns certain worldwide rights to the FC2 Female Condom®, including patents that have been issued in the U.S., the European Union, Canada, Australia, South Africa, Japan, The People's Republic of China, Spain, Mexico, Greece, Turkey and by the African Regional Intellectual Property Organization (ARIPO), which includes Botswana, The Gambia, Ghana, Kenya, Lesotho, Malawi, Mozambique, Namibia, Sierra Leone, Somalia, Sudan, Swaziland, Uganda, United Republic of Tanzania, Zambia and Zimbabwe. FC2 patent applications are pending in various countries. The FC2 Female Condom® is the only available FDA-approved product controlled by a woman that offers dual protection against sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy. The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies. |
